Skip to main content
SpringerLink
Log in

Clinical Pharmacology of the Retinoids

  • Conference paper
Book cover Retinoids in Oncology

Part of the book series: ESO Monographs ((ESO MONOGRAPHS))

Abstract

Positive results achieved with retinoids in the chemoprevention of epithelial cancer as well as in the treatment of acute promyelocytic leukaemia and squamous cancers of the skin and cervix have stimulated interest in the pharmacological aspects of these substances. The use of retinoids in clinical oncology and particularly in chemoprevention poses specific problems of tolerability, whether the agents are used singly or in combination with other anticancer drugs. A particular characteristic of cancer chemoprevention is the requirement for precise assessment of metabolic and toxicologic profiles related to long-term administration.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Muindi J, Frankel S, Huselton C et al: Clinical pharmacology of oral all-trans retinoic acid in patients with acute promyelocytic leukemia. Cancer Res 1992 (52):2138–2142

    PubMed  CAS  Google Scholar 

  2. Brazzell RK, Vane FM, Ehmann CW, Colburn WA: Pharmacokinetics of isotretinoin during repetitive dsing to patients. Eur J Clin Pharmacol 1983 (24): 695–702

    Article  PubMed  CAS  Google Scholar 

  3. Formelli F, Clerici M, Campa T et al: Five-year administration of fenretinide: pharmacokinetics and effects on plasma retinol concentrations. J Clin Oncol 1993 (11):2036–2042

    PubMed  CAS  Google Scholar 

  4. Massarella JW and Vane FM: Etretinate kinetics during chronic dosing in severe psoriasis. Clin Pharmacol Ther 1985 (37):439–446

    Article  PubMed  CAS  Google Scholar 

  5. Wiegand UW, Busslinger AA, Chou RC, Jensen BK: The pharmacokinetics of acitretin in humans: an update. In: Livrea MA and Packer L (eds) Retinoids. Progress in Research and Clinical Application. Marcel Dekker Inc, New York 1993 pp 617–628

    Google Scholar 

  6. Goodman DS: Vitamin A and retinoids in health and disease. N Engl J Med 1984 (310):1023–1031

    Article  PubMed  CAS  Google Scholar 

  7. Blomhoff R, Green MH, Green JB, Berg T, Norum KR: Vitamin A metabolism: new perspectives on absorption, transport and storage. Physiol Rev 1991 (71):951–990

    PubMed  CAS  Google Scholar 

  8. Wald NJ, Cuckle HS, Barlow RD et al: The effect of vitamin A supplementation on serum retinol and retinol-binding protein levels. Cancer Lett 1985 (29): 203–213

    Article  PubMed  CAS  Google Scholar 

  9. Goodman GE, Alberts DS, Peng YM et al: Pharmacokinetics and phase I trial of retinol and 13- cis-retinoic acid. In: Meyskens FL and Prasad KN (eds) Modulation and Mediation of Cancer by Vitamins. Karger, Basel 1983 pp 311–316

    Google Scholar 

  10. Plezia PM, Alberts DS, Peng YM et al: The role of serum and tissue pharmacology studies in the design and interpretation of chemoprevention trials. Preventive Medicine 1989 (18):680–687

    Article  PubMed  CAS  Google Scholar 

  11. Infante M, Pastorino U, Chiesa G et al: Laboratory evaluation during high-dose vitamin A administration: a randomised study on lung cancer patients after surgical resection. J Cancer Res Clin Oncol 1991 (117):156–162

    Article  PubMed  CAS  Google Scholar 

  12. Korner WF and Vollm J: New aspects of the tolerance of retinol in humans. Int J Vit Nutr Res 1975 (45):363–372

    CAS  Google Scholar 

  13. Fidge NH, Shiratori T, Ganguly J, Goodman DS: Pathways of absorption of retinal and retinoic acid in the rat. J Lipid Res 1968 (9):103–109

    PubMed  CAS  Google Scholar 

  14. Wathne KO, Norum KR, Smeland E, Blomhoff R: Retinol bound to physiological carrier molecules regulates growth and differentiation of myeloid leukemic cells. J Biol Chem 1988 (263):8691–8695

    PubMed  CAS  Google Scholar 

  15. Pastorino U, Chiesa G, Infante M et al: Safety of high-dose vitamin A. Randomized trial on lung cancer chemoprevention. Oncology 1991 (48):131–137

    Article  PubMed  CAS  Google Scholar 

  16. Huang ME, Ye YC, Chen JR et al: Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 1988 (72):567–572

    PubMed  CAS  Google Scholar 

  17. Castaigne S, Chomienne C, Daniel MT et al: All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia: I. Clinical results. Blood 1990 (76):1704–1709

    PubMed  CAS  Google Scholar 

  18. Warrell RP Jr, Frankel SR, Miller WH Jr et al: Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans retinoic acid). N Engl J Med 1991 (324):1385–1393

    Article  PubMed  Google Scholar 

  19. Ohno R, Yoshida H, Naoe T et al: All-trans retinoic acid (ATRA) as a differentiation therapy for refractory acute promyelocytic leukemia (APL). Proc Am Assoc Cancer Res 1992 (33):234

    Google Scholar 

  20. White KL, Wiley JS, Frost T et al: All-trans retinoic acid in the treatment of acute promyelocytic leukaemia. Aust NZ J Med 1992 (22):449–454

    CAS  Google Scholar 

  21. Fenaux P, Le Dely MC, Castaigne S et al: Effect of all-trans retinoic acid in newly diagnosed acute promyelocytic leukemia: results of a multicenter randomized trial. Blood 1993 (82);3241–3249

    PubMed  CAS  Google Scholar 

  22. Warrell RP Jr, de Thè H, Wang Z-Y, Degos L: Acute promyelocytic leukemia. N Engl J Med 1993 (329):177–189

    Article  PubMed  CAS  Google Scholar 

  23. Frankel SR, Eardley A, Heller G et al: All-trans retinoic acid for acute promyelocytic leukemia: results of the New York study. Ann Intern Med 1994 (120):278–286

    PubMed  CAS  Google Scholar 

  24. Fenaux P, Castaigne S, Dombret H et al: All-trans retinoic acid followed by intensive chemotherapy gives a high complete remission rate and may prolong remissions in newly diagnosed acute promyelocytic leukemia: a pilot study on 26 cases. Blood 1992 (80):2176–2181

    PubMed  CAS  Google Scholar 

  25. Muindi J, Frankel SR, Miller WH Jr et al: Continuous treatment with all-trans retinoic acid causes a progressive reduction in plasma concentrations: implications for relapse and retinoid “resistance” in patients with acute promyelocytic leukemia. Blood 1992 (79):299–303

    PubMed  CAS  Google Scholar 

  26. Delva L, Cornic M, Balitrand N et al: Resistance to all-trans retinoic acid (ATRA) therapy in relapsing acute promyelocytic leukemia: study of in vitro ATRA sensitivity and cellular retinoic acid binding protein levels in leukemic cells. Blood 1993 (82):2175–2181

    PubMed  CAS  Google Scholar 

  27. Cornic M, Delva L, Guidez F, Balitrand N, Degos L, Chomienne C: Induction of retinoic acid-binding protein in normal and malignant human myeloid cells by retinoic acid in acute promyelocytic leukemia patients. Cancer Res 1992 (52):3329–3334

    PubMed  CAS  Google Scholar 

  28. Lefebvre P, Thomas G, Gourmel B et al: Pharmacokinetics of oral all-trans retinoic acid in patients with acute promyelocytic leukemia. Leukemia 1991 (5):1054–1058

    PubMed  CAS  Google Scholar 

  29. Rigas JR, Francis PA, Muindi JRF et al: Constitutive variability in catabolism of the natural retinoid, all-trans retinoic acid, and its modulation by ketoconazole. JNCI 1993 (85):1921–1926

    PubMed  CAS  Google Scholar 

  30. Miller VA, Rigas JR, Muindi JRF et al: Modulation of all-trans retinoic acid pharmacokinetics by liarazole. Cancer Chemother Pharmacol 1994 (in press)

    Google Scholar 

  31. Muindi JF and Young CW: Lipid hydroperoxides greatly increase the rate of oxidative catabolism of all-trans retinoic acid by human cell culture microsomes genetically enriched in specified cytochrome P-450 isoforms. Cancer Res 1993 (53): 1226–1229

    PubMed  CAS  Google Scholar 

  32. Fiorella PD and Napoli JL: Expression of cellular retinoic acid binding protein (CRABP) in Escherichia coli: Characterization and evidence that holo-CRABP is a substrate in retinoic acid metabolism. J Biol Chem 1991 (266): 16572–16579

    PubMed  CAS  Google Scholar 

  33. Boylan JF and Gudas LJ: The level of CRABP-I expression influences the amounts and types of all-trans retinoic acid metabolites in F9 teratocarcinoma stem cells. J Biol Chem 1992 (267):21486

    Google Scholar 

  34. Warrell RP Jr: Acquired retinoid resistance in acute promyelocytic leukemia: new mechanisms, strategies, and implications. Blood 1993 (82):1949–1953

    PubMed  CAS  Google Scholar 

  35. Robertson KA, Emami B, Collins SJ: Retinoic acidresistant HL-60R cells harbor a point mutation in the retinoic acid receptor ligand-binding domain that confers dominant negative activity. Blood 1992 (80):1885–1889

    PubMed  CAS  Google Scholar 

  36. Dermine S, Grignani F, Clerici M et al: Occurrence of resistance to retinoic acid in the acute promyelocytic cell line NB306 is associated with altered expression of the PML/RAR-a protein. Blood 1994 (in press)

    Google Scholar 

  37. Kerr IG, Lippman ME, Jenkins J, Myers C: Pharmacology of 13-cis-retinoic acid in humans. Cancer Res 1982 (42):2069–2073

    PubMed  CAS  Google Scholar 

  38. Khoo KC, Reik FD, Colburn WA: Pharmacokinetic profile of isotretinoin following a single oral dose to normal man. J Clin Pharmacol 1982 (22):395–402

    Article  PubMed  CAS  Google Scholar 

  39. Berni R, Clerici M, Malpeli G, Cleris L, Formelli F: Retinoids: in vitro interaction with retinol-binding protein and influence on plasma retinol. FASEB J 1993 (7):1179–1184

    PubMed  CAS  Google Scholar 

  40. Desiraju RK, Scott V, Nayak RK, Minn FL: Pharmacokinetics of fenretinide in healthy volunteers. Clin Pharmacol Ther 1985 (37/2): 190

    Google Scholar 

  41. Johnson & Johnson: Fenretinide. Drugs of the Future 1987 (12/3):305–306

    Google Scholar 

  42. Peng YM, Dalton WS, Alberts DS et al: Pharmacokinetics of N-4-hydroxyphenyl-retinamide and the effect of its oral administration on plasma retinol concentrations in cancer patients. Int J Cancer 1989 43:22–26 Erratum: Int J Cancer 1989 (44):567

    Article  PubMed  CAS  Google Scholar 

  43. Formelli F, Carsana R, Costa A et al: Plasma retinol level reduction by the synthetic retinoid fenretinide: a one year follow-up study of breast cancer patients. Cancer Res 1989 (49):6149–6152

    PubMed  CAS  Google Scholar 

  44. Doose DR, Minn FL, Stellar S, Nayak RK: Effects of meals and meal composition on the bioavailability of fenretinide. J Clin Pharmacol 1992 (32): 1089–1095

    PubMed  CAS  Google Scholar 

  45. Formelli F, Carsana R, Costa A: N-(4hydroxy-phenyl)retinamide (4-HPR) lowers plasma retinol levels in rats. Med Sci Res 1987 (15):843–844

    CAS  Google Scholar 

  46. Dimitrov NV, Meyer CJ, Perloff M et al: Alteration of retinol-binding-protein concentrations by the synthetic retinoid fenretinide in healthy human subjects. Am J Clin Nutr 1990 (51):1082–1087

    PubMed  CAS  Google Scholar 

  47. Kaiser-Kupfer Ml, Peck GL, Caruso RC: Abnormal retinal function associated with fenretinide, a synthetic retinoid. Arch Ophtalmol 1986 (104):69–70

    CAS  Google Scholar 

  48. Costa A, Malone W, Perloff M et al: Tolerability of the synthetic retinoid fenretinide (HPR). Eur J Cancer Clin Oncol 1989 (25):805–808

    Article  PubMed  CAS  Google Scholar 

  49. Kingstone TP, Lowe NJ, Winston J, Heckenlively J: Visual and cutaneous toxicity which occurs during n-(4hydroxyphenyl)retinamide therapy for psoriasis. Clin Exper Dermatol 1986 (11):624–627

    Article  Google Scholar 

  50. Modiano RM, Dalton WS, Lippman SM et al: Phase II study of fenretinide (N-[4 hydroxyphenyl]retin-amide) in advanced breast cancer and melanoma. Inv New Drugs 1990 (8):317–319

    CAS  Google Scholar 

  51. Decensi A, Torrisi R, Polizzi A et al: Effect of the synthetic retinoid fenretinide on dark adaptation and the ocular surface. JNCI 1994 (86): 105–110

    PubMed  CAS  Google Scholar 

  52. Veronesi U, De Palo G, Costa A et al: Chemoprevention of breast cancer with retinoids. JNCI Monogr 1992 (12):93–97

    Google Scholar 

  53. Chiesa F, Tradati N, Marazza M et al: Prevention of local relapses and new localisations of oral leukoplakias with the synthetic retinoid fenretinide (4- HPR). Preliminary results. Oral Oncol, Eur J Cancer 1992 (28B):97–102

    Google Scholar 

  54. Berni R and Formelli F: In vitro interaction of fenretinide with plasma retinol-binding protein and its functional consequences. FEBS 1992 308:43–45

    Article  CAS  Google Scholar 

  55. Smith JH, Carpenter Lawless D, Green MH, Moon RC: Secretion of vitamin A and retinol-binding protein into plasma is depressed in rats by N-(4- hydroxyphenyl)retinamide (Fenretinide). J Nutr 1992 (122): 1999–2009

    PubMed  CAS  Google Scholar 

  56. Torrisi R, Pensa F, Orengo MA, Catsafados E et al: The synthetic retinoid fenretinide lowers plasma insulin-like growth factor I levels in breast cancer patients. Cancer Res 1993 (53):4769–4771

    PubMed  CAS  Google Scholar 

  57. Mehta RG, Moon RC, Hawthorne M, Formelli F, Costa A: Distribution of fenretinide in the mammary gland of breast cancer patients. Eur J Cancer 1991 (27):138–141

    Article  PubMed  CAS  Google Scholar 

  58. Moon RC, Thompson HJ, Becci PJ et al: N-(4 hydroxyphenyl)retinamide, a new retinoid for prevention of breast cancer. Cancer Res 1979 (39):1339–1346

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Thoracic Surgery, Istituto Nazionale Tumori, Via Venezian 1, 20133, Milan, Italy

    Ugo Pastorino

  2. Department of Medicine, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, 10021, New York, NY, USA

    Raymond P. Warrell Jr.

  3. Department of Experimental Oncology B, Istituto Nazionale Tumori, Via Venezian 1, 20133, Milan, Italy

    Franca Formelli

Authors
  1. Ugo Pastorino
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Raymond P. Warrell Jr.
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Franca Formelli
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Hôpital St. Louis, Institut Universitaire d’Hématologie, 1, Avenue Claude Vellefaux, 75010, Paris, France

    Laurent Degos

  2. Investigational Drug Branch, Division of Cancer Treatment, National Cancer Institute, 6130 Executive Boulevard, 20892, Rockville, MD, USA

    David R. Parkinson M.D.

Rights and permissions

Reprints and permissions

Copyright information

© 1995 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Pastorino, U., Warrell, R.P., Formelli, F. (1995). Clinical Pharmacology of the Retinoids. In: Degos, L., Parkinson, D.R. (eds) Retinoids in Oncology. ESO Monographs. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-79706-4_5

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-79706-4_5

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-79708-8

  • Online ISBN: 978-3-642-79706-4

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation